FDA Grants Accelerated Approval to Tabrecta (capmatinib) for Metastatic Non-small Cell Lung Cancer with a Change in MET

On May 6^th, 2020, the Food and Drug Administration (FDA) approved Tabrecta (capmatinib) for treatment of advanced non-small cell lung cancer (NSCLC) with a change in MET. The FDA based their approval on the results of the clinical trial GEOMETRY mono-1 which showed that more patients receiving Tabrecta experienced a response to the treatment than those on chemotherapy alone. In addition, the response lasted for a longer time.

Tabrecta is the first drug approved by the FDA to treat patients whose cancer has the unique MET exon-14 skipping mutation. In addition to the approval for this novel treatment, the FDA has approved the next generation sequencing technology, FoundationOne CDx, as the official companion diagnostic for Tabrecta.

Click here to read the full press release.